A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse
This is a clinical trial of investigational drug PF-04449913 which will be administered orally.
IRB Protocol #
Leukemia Lymphoma Society (LLS)
EMILY DENONCOURT at (303)748-0566 or EMILY.DENONCOURT@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period will determine eligibility. The treatment period will consist of 28 day cycles for as long as your doctor determines you are still benefitting from the treatment. The follow- up period will consist of one final visit to the clinic. // Eligibility criteria include but are not limited to 18 years or older with Acute Leukemia and high risk of post-allogeneic stem cell transplantation relapse.Eligibility criteria include but are not limited to 18 years or older with Acute Leukemia and high risk of post-allogeneic stem cell transplantation relapse.